文献速递妇科生殖医学

口服避孕药对多囊卵巢综合征临床与生化表现影响的交叉随机对照试验

A comparison of the effects of oral contraceptives on the clinical and biochemical manifestations of polycystic ovary syndrome: a crossover randomized controlled trial.
PubMed 文献 · Hum Reprod · 2020-01-01

该研究为六臂交叉随机对照试验,纳入200例多囊卵巢综合征患者,比较含左炔诺孕酮与含去氧孕烯、环丙孕酮或屈螺酮的口服避孕药效果。结果显示三类药对高雄激素临床表现改善相似,但左炔诺孕酮产品对雄激素谱效果较差且对血脂有不良影响。

要点

  • 含去氧孕烯、环丙孕酮或屈螺酮的口服避孕药降低游离雄激素指数优于含左炔诺孕酮者。
  • 含左炔诺孕酮的口服避孕药对血脂谱有不良影响,而屈螺酮产品改善血脂更明显。
  • 临床选择口服避孕药治疗多囊卵巢综合征时,优先考虑低雄激素或抗雄激素孕激素产品。

核心结论

  • 三种口服避孕药对高雄激素临床表现改善相似,但含左炔诺孕酮产品对雄激素谱效果较差且对血脂有不良影响。

研究设计与样本

  • 交叉随机对照六臂试验,纳入200例18-45岁多囊卵巢综合征患者,每个治疗周期6个月,试验于2016年2月至2018年1月在伊朗进行。

主要发现

  • 治疗3个月后,含去氧孕烯(95%CI:-2.3,-1.0)、环丙孕酮(95%CI:-2.4,-1.1)和屈螺酮(95%CI:-2.6,-1.4)的口服避孕药降低游离雄激素指数优于含左炔诺孕酮者(P<0.001)。
  • 治疗6个月后,含去氧孕烯(95%CI:-3.6,-1.5)、环丙孕酮(95%CI:-3.1,-0.8)和屈螺酮(95%CI:-3.4,-1.1)的口服避孕药降低游离雄激素指数优于含左炔诺孕酮者(P<0.001)。
  • 使用含去氧孕烯、环丙孕酮和屈螺酮的口服避孕药3-6个月,性激素结合球蛋白升高幅度高于含左炔诺孕酮者(P<0.001)。
  • 使用含去氧孕烯(P=0.003)、环丙孕酮(P=0.012)和屈螺酮(P<0.001)的口服避孕药6个月,硫酸脱氢表雄酮水平下降幅度大于含左炔诺孕酮者。
  • 使用含屈螺酮的口服避孕药6个月,痤疮改善优于含左炔诺孕酮者(P=0.007);使用含环丙孕酮和屈螺酮的口服避孕药3个月,甘油三酯和高密度脂蛋白水平较高、低密度脂蛋白水平较低(P<0.05)。

临床怎么用

  • 临床治疗多囊卵巢综合征时,如条件允许,优先选择含低雄激素或抗雄激素孕激素的口服避孕药。

局限性

  • 研究基于雄激素 Excess Society 标准诊断的患者,结果可能不适用于 Rotterdam 标准诊断的轻度表型。
  • 研究存在脱落率高、缺乏金标准雄激素检测方法以及多终点比较的局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Do oral contraceptives (OCs) containing progestins with low androgenic or antiandrogenic activities have different effects to those containing levonorgestrel (LNG) on clinical, androgenic and metabolic manifestations of polycystic ovarian syndrome (PCOS)? SUMMARY ANSWER: The three OCs tested had similar effects on clinical findings of hyperandrogenism (HA), whereas products containing LNG were less effective on androgenic profiles and had detrimental effects on lipid profiles. WHAT IS KNOWN ALREADY: Despite data available on the effects of OCs, the superiority of products with low androgenic or antiandrogenic progesterone components in comparison with older products used in women with PCOS has not been clarified. STUDY DESIGN, SIZE, DURATION: This study is a crossover randomized controlled six-arm trial, with all six arms including two 6-month treatment periods, one period with OCs containing LNG, and the other with one of three OCs containing desogestrel (DSG), cyproterone acetate (CPA) or drospirenone (DRSP). The trial was conducted between February 2016 and January 2018 and enrolled 200 patients with PCOS. PARTICIPANTS/MATERIALS, SETTING, METHODS: Two hundred women with PCOS (ages 18-45 years) were recruited at the endocrine outpatient clinic of the Research Institute for Endocrine Sciences (RIES) of the Shahid Beheshti University of Medical Sciences, Tehran, Iran. A blocking or stratification random allocation (block size = 6) using a computer-based random number generator was prepared to assign participants to treatment groups. Both the clinical examiner and data analyst were blinded to participants during the trial. Outcomes of interest, including anthropometric and clinical manifestations and hormonal, and biochemical parameters were assessed at baseline, after 3 and 6 months of each treatment and after the washout period. MAIN RESULTS AND THE ROLE OF CHANCE: This study detected a higher decrease in free-androgen index (FAI) levels after 3 months of treatment with OCs containing DSG (95% CI: -2.3, -1.0), CPA (95% CI: -2.4, -1.1) and DRSP (95% CI: -2.6, -1.4), compared with products containing LNG (P < 0.001). Use of OCs containing DSG (95% CI: -3.6, -1.5), CPA (95% CI: -3.1, -0.8) and DRSP (95% CI: -3.4, -1.1) for 6 months was associated with more decrease in FAI, compared with products containing LNG (P < 0.001). The study showed that use of OCs containing DSG, CPA and DRSP for 3-6 months was associated with a higher increase of sex hormone-binding globulin (SHBG), compared with products containing LNG (P < 0.001). We also observed more decrease in dehydroepiandrosterone sulfate levels after use of OCs containing DSG (P = 0.003), CPA (P = 0.012) and DRSP (P < 0.001) for 6 months, compared with products containing LNG. Our results showed that the use of OCs containing DRSP for 6 months was associated with more improvement in acne, compared with products containing LNG (P = 0.007). Women treated with OCs containing CPA, and DRSP for 3 months had higher TG and HDL levels and lower LDL levels, compared with those treated with products containing LNG (P < 0.05). After 6 months of treatment, patients treated with OCs containing DRSP had a sharper decline in LDL levels and more increase in HDL levels, compared to those treated with products containing LNG (P = 0.001). LIMITATIONS, REASONS FOR CAUTION: Considering this trial was conducted in women diagnosed with Androgen Excess Society criteria, the results may not be generalizable for mild phenotypes diagnosed using Rotterdam criteria. Other limitations of the study include the high dropout rate, the lack of a gold standard androgen assay and the multiple end points. WIDER IMPLICATIONS OF THE FINDINGS: Our results support the views of clinicians, who suggest an OC with a low androgenic or antiandrogenic progestin, if available, to treat PCOS. STUDY FUNDING/COMPETING INTEREST(S): This study was supported by the RIES, Shahid Beheshti University of Medical Sciences, Tehran, Iran. There are no conflicts of interest. TRIAL REGISTRATION NUMBER: IRCT201702071281N2. TRIAL REGISTRATION DATE: 21 February 2017. DATE OF FIRST PATIENT’S ENROLMENT: 21 March 2017.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Amiri M, Nahidi F, Bidhendi-Yarandi R, et al. A comparison of the effects of oral contraceptives on the clinical and biochemical manifestations of polycystic ovary syndrome: a crossover randomized controlled trial. Hum Reprod. 2020. PMID: 31916574. doi:10.1093/humrep/dez255

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。